Novo Nordisk says Metsera bid won't raise antitrust issues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Novo Nordisk earnings preview: Barclays and BofA weigh in
November 4, 2025 4:00 PM ESTBarclays and Bank of America both expect Novo Nordisk's (NYSE: NVO) third-quarter results on November 5 to come broadly in line with expectations but warn the drugmaker could lower the upper end of its 2025 guidance as prescription trends soften.
Barclays analyst Yihan Li said the bank now models +10.9% FY25 topline CER growth (generally in-line with guidance... More
